Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Sonia Extremera"'
Autor:
Carmen Kahatt, Cinthya Coronado, Pilar Lardelli, Claudia Silvia Corrado, Elena Roy, Vicente Alfaro, Bernardo Miguel-Lillo, Sonia Extremera, Arturo Soto-Matos, Sergio Szyldergemajn
Publikováno v:
Marine Drugs, Vol 9, Iss 6, Pp 1007-1023 (2011)
Plitidepsin is a cyclic depsipeptide of marine origin in clinical development in cancer patients. Previously, some depsipeptides have been linked to increased cardiac toxicity. Clinical databases were searched for cardiac adverse events (CAEs) that o
Externí odkaz:
https://doaj.org/article/71d4efc9e46b416b8d484543c69d0239
Autor:
Sergio Szyldergemajn, Jean P. Droz, Sonia Extremera, Patrick Schöffski, Joan Carles Galceran, Enrique Gallardo, Stephane Culine, Aude Fléchon, Herlinde Dumez
Publikováno v:
Marine Drugs, Vol 7, Iss 3, Pp 451-463 (2009)
The objective of this exploratory, open-label, single-arm, phase II clinical trial was to evaluate plitidepsin (5 mg/m2) administered as a 3-hour continuous intravenous infusion every two weeks to patients with locally advanced/metastatic transitiona
Externí odkaz:
https://doaj.org/article/3107190c22d943c79faed5180c714079
Autor:
Vincent Ribrag, Dolores Caballero, Christophe Fermé, Emanuele Zucca, Reyes Arranz, Javier Briones, Christian Gisselbrecht, Gilles Salles, Alessandro M. Gianni, Henry Gomez, Carmen Kahatt, Claudia Corrado, Sergio Szyldergemajn, Sonia Extremera, Bernardo de Miguel, Martin Cullell-Young, Franco Cavalli
Publikováno v:
Haematologica, Vol 98, Iss 3 (2013)
This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m2 administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refractory aggressive
Externí odkaz:
https://doaj.org/article/c58afd14cd994b96ba309fccf26fa18d
Autor:
Enrique M. Ocio, Angelo Michele Carella, Maria-Victoria Mateos, Argiris Symeonidis, Heather Oakervee, Raymond H. Banh, Chang-Ki Min, Roman Hájek, Richard Greil, Pieter Sonneveld, Shang-Yi Huang, Carmen Kahatt, Ivan Spicka, Nathalie Meuleman, Sonia Extremera, James D'Rozario, Paul Cannell, Sara Martinez, Meletios A. Dimopoulos, Heinz Ludwig, Vicente Alfaro
Publikováno v:
Annals of Hematology
Annals of Hematology, 98(9), 2139-2150. Springer-Verlag
Annals of hematology
Annals of hematology, 98 (9
Annals of Hematology, 98(9), 2139-2150. Springer-Verlag
Annals of hematology
Annals of hematology, 98 (9
The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib and l
Autor:
Carmen Kahatt, Luis Paz-Ares, Inmaculada Sanchez-Simon, Elizabeth Jimenez Aguilar, Rafael Nuñez, Santiago Ponce Aix, Sonia Extremera, Alejandro Falcon Gonzalez, Jesus R Fernandez, Elena Brehcist, Julia Martinez, Ali Zeaiter, Gregory M. Cote
Publikováno v:
Journal of Clinical Oncology. 39:5586-5586
5586 Background: LUR is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in combination with IRI has been reported, thus promptin
Autor:
Ahmad Awada, Marc Espié, Miguel Martín, Mafalda Oliveira, Philippe Aftimos, Pilar Lardelli, Eva E.M. Fernández-García, Sonia Extremera, Javier Cortes, Sara López-Tarruella, Suzette Delaloge
Publikováno v:
Clinical Breast Cancer. 16:364-371
Background Preclinical and clinical data suggest that xeroderma pigmentosum G gene (XPG) status might predict trabectedin efficacy. This phase 2 study evaluated the efficacy of trabectedin at a dose of 1.3 mg/m 2 as a 3-hour intravenous infusion ever
Autor:
José Baselga, Silvia Antolín, Carmen Kahatt, Sergio Szyldergemajn, Judy Garber, Nadine Tung, Cristian Fernandez, Cristina Cruz, Steven J. Isakoff, J Balmaña, Arturo Soto Matos, Ana Lluch, Sonia Extremera, José Alejandro Pérez Fidalgo
Publikováno v:
Cancer Research. 75:P3-13
Background: Metastatic breast cancer (MBC) is a clinically heterogeneous disease in which selective approaches are needed to identify patients (pts) who will benefit the most from available therapies and avoid unnecessary toxicities. Lurbinectedin (P
Autor:
Antoine Hollebecque, Sonia Extremera, Gilles Salles, Vicente Alfaro, Sandrine Aspeslagh, Mark N. Stein, Emmanuel Gyan, Salvador Fudio, Rastilav Bahleda, Arturo Soto-Matos, Jean-Charles Soria
Publikováno v:
Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩
International audience; This phase I trial evaluated the combination of the marine-derived cyclodepsipeptide plitidepsin (trade name Aplidin) with sorafenib or gemcitabine in advanced cancer and lymphoma patients. The study included two treatment arm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23b85d24896c8e6b050b4cfb9ec050c
https://hal.archives-ouvertes.fr/hal-01791282
https://hal.archives-ouvertes.fr/hal-01791282
Autor:
Franco Cavalli, Henry L. Gomez, Carmen Kahatt, Emanuele Zucca, Sergio Szyldergemajn, Reyes Arranz, Martin Cullell-Young, Christophe Fermé, Dolores Caballero, Bernardo de Miguel, Vincent Ribrag, Claudia Corrado, Javier Briones, Sonia Extremera, Alessandro M. Gianni, Christian Gisselbrecht, Gilles Salles
Publikováno v:
HAEMATOLOGICA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
This phase II clinical trial evaluated the efficacy, safety and pharmacokinetics of plitidepsin 3.2 mg/m(2) administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks in 67 adult patients with relapsed/refractory aggressiv
Publikováno v:
Journal of Clinical Oncology. 36:8018-8018
8018Background: Plitidepsin is a synthetic cyclic depsipeptide isolated from the marine tunicate Aplidium albicans targeting the proto-oncogene eEF1A2, which is over-expressed in multiple myeloma c...